GLOW is a multi-peptide formulation designed for laboratory use, combining three well-characterized compounds into a single vial. The GLOW peptide blend includes GHK-Cu, BPC-157, and TB500, each selected for its relevance in cellular and tissue-related research.
These peptides differ structurally: GHK-Cu is a copper-binding tripeptide, BPC-157 is a synthetic pentadecapeptide, and TB500 is a larger peptide derived from thymosin beta proteins. This combination supports the study of multiple peptide systems within controlled experimental models.
In research environments, the GHK-Cu BPC-157 TB500 blend is supplied as a lyophilized powder, prepared to high-purity standards, enabling consistent handling and precise preparation. Researchers often evaluate how combined peptide systems interact within biological pathways related to cellular signaling, structural organization, and coordinated responses. This formulation is commonly used in experimental setups designed to examine multi-peptide dynamics under defined laboratory conditions.
GLOW – GHK-CU (50mg) / BPC-157 (10mg) / TB500 (10mg) Key Features & Specs
- Subcategory: Healing & Regenerative Peptides
- Strength: 70mg
- CAS Numbers
- GHK-Cu: 89030-95-5
- BPC-157: 137525-51-0
- TB500: 77591-33-4
- Chemical Formulas
- GHK-Cu: C₁₄H₂₁N₆O₄Cu
- BPC-157: C₆₂H₉₈N₁₆O₂₂
- TB500: C₂₁₂H₃₅₀N₅₆O₇₈S
- Molecular Weights
- GHK-Cu:91 g/mol
- BPC-157:535 g/mol
- TB500 (TB-4):4408 g/mol
- Peptide Sequences
- GHK-Cu: Gly-His-Lys (GHK)
- BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- TB500: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser
For laboratory research use only.
GLOW – GHK-CU (50mg) / BPC-157 (10mg) / TB500 (10mg) Research Uses
This formulation is being studied for its combined interaction with biological systems involved in cellular repair, tissue structure, and molecular signaling. GLOW is often examined in studies exploring how multiple peptides influence interconnected biological processes.
Researchers investigate how this blend interacts with systems related to tissue maintenance, cellular communication, and structural protein activity. These studies are typically conducted in controlled laboratory models, such as cell cultures or preclinical environments.
The GHK-Cu BPC-157 TB500 blend is also being explored for its potential to coordinate responses across biological pathways related to connective tissue, cellular regeneration, and signaling networks.
GLOW – GHK-CU (50mg) / BPC-157 (10mg) / TB500 (10mg) Insights & Observed Findings
Experimental studies involving peptide combinations have evaluated how multiple compounds behave within the same research model. Investigations using the GLOW peptide blend often focus on how each component contributes to observed cellular responses under controlled conditions.
In GLOW research, studies of peptide blends typically examine concentration ranges and exposure conditions to evaluate changes in cellular signaling, protein expression, and tissue-related markers. Observations are collected using in vitro models or preclinical systems designed to monitor biological activity.
Research involving the GHK-Cu BPC-157 TB500 blend continues to explore how peptide combinations influence coordinated biological responses, contributing to ongoing research into multi-peptide systems.
GLOW – GHK-CU (50mg) / BPC-157 (10mg) / TB500 (10mg) Handling & Storage
This peptide blend should be handled using standard laboratory procedures appropriate for multi-component peptide formulations. The lyophilized material is typically stored at approximately –20°C and protected from light and moisture prior to preparation.
Researchers should allow the vial to reach room temperature before opening to minimize exposure to condensation. After reconstitution, use the prepared solution promptly.
Proper handling is recommended throughout GLOW research blend peptide protocols to maintain the integrity of each component during laboratory procedures.
Compliance Notice: This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.
References
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract and wound healing. Curr Pharm Des. 2011;17(16):1612-1632. doi:10.2174/138161211796197179.
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987.
- Bajramagic S, Sever M, Rasic F, et al. Stable gastric pentadecapeptide BPC 157 and intestinal anastomoses therapy in rats—A review. Pharmaceuticals (Basel). 2024;17(8):1081. Published 2024 Aug 17. doi:10.3390/ph17081081.
- Adnan SB, Maarof M, Fauzi MB, Fadilah NIM. Exploring the role of tripeptides in wound healing and skin regeneration: a comprehensive review. Int J Med Sci. 2025;22(16):4175-4200. Published 2025 Oct 1. doi:10.7150/ijms.11811.
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151. doi:10.1096/fj.09-142307
- Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-481. doi:10.1096/fasebj.11.6.9194528